Areteia Therapeutics vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Areteia Therapeutics (formerly TPI) is developing dexpramipexole, an oral eosinophil-depleting drug for eosinophilic asthma and EGPA; raised $215M in a Series B in 2023; Phase 3 EXHALE trial ongoing;
About
Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral treatments for eosinophil-driven diseases, particularly severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). The company was formerly known as TPI Therapeutics and rebranded as Areteia upon securing significant venture financing. Its lead compound, dexpramipexole, is a small molecule that selectively inhibits eosinophil maturation in the bone marrow — reducing circulating eosinophil levels by 75-90% without the immunosuppressive effects that can accompany broad anti-inflammatory drugs.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.